{"id":53078,"date":"2023-01-19T11:02:49","date_gmt":"2023-01-19T10:02:49","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/"},"modified":"2023-01-19T11:02:49","modified_gmt":"2023-01-19T10:02:49","slug":"vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/","title":{"rendered":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nAnnogen to develop multiple CNS-cell specific promoters for VectorY programs\n<\/li>\n<\/ul>\n<p>AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind the SuRE<sup>\u2122<\/sup> technology, today announced a research collaboration for the identification of CNS-cell specific synthetic promoters for use in VectorY\u2019s vectorized antibody programs.\n<\/p>\n<p>\nUsing its proprietary Survey of Regulatory Elements (SuRE<sup>\u2122<\/sup>) technology, Annogen functionally annotates the entire human non-coding genome to identify regulatory DNA elements that control therapeutic gene expression for gene &amp; cell therapy. Hundreds of millions of DNA elements are screened for their ability to serve as promoters or enhancers, driving gene expression in a cell- or disease-specific manner. The SuRE<sup>\u2122<\/sup> technology is unique among other promoter-identification technologies in functionally testing non-coding promoter elements throughout the entire genome, including at remote sites where activity is regulated.\n<\/p>\n<p>\n\u201cWe are delighted to work together with Annogen on novel tailored cell-specific promoters to enhance VectorY\u2019s transformative AAV-vectorized antibody platform and its potential to yield disease-modifying treatments for neurodegenerative diseases such as ALS\u201d, Sander van Deventer CEO of VectorY said.\n<\/p>\n<p>\nVectorY is a leader in the development of transformative vectorized antibody therapies for neurodegenerative diseases with high unmet medical need. With extensive internal knowhow, a unique proprietary platform has been assembled that combines state-of-the-art therapeutic antibodies, capsids, and manufacturing to enable efficient delivery of one-time precision treatments to the CNS. VectorY is advancing a pipeline of potentially disease-modifying treatments for devastating neurodegenerative diseases, including ALS, Huntington\u2019s, and Parkinson\u2019s disease.\n<\/p>\n<p>\n\u201cVectorY is a leading example of novel advanced approaches to vectorized antibody therapy development,\u201d Joris van Arensbergen CEO of Annogen adds. \u201cTheir focus on controlling various aspects of vector design, including cell-specific promoters, proves the value we can bring with our SuRE<sup>\u2122<\/sup> technology. We are very pleased to work with this forward-thinking team and further build our track record in this field.\u201d\n<\/p>\n<p class=\"bwalignc\">\n<b>-Ends-<\/b>\n<\/p>\n<p>\n<b>About VectorY<br \/>\n<br \/><\/b>VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington\u2019s disease. For more information, see <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.vectorytx.com%2F&amp;esheet=53281464&amp;newsitemid=20230119005364&amp;lan=en-US&amp;anchor=www.vectorytx.com&amp;index=1&amp;md5=d23e282d89eb5a57e1a2673c4866a5cd\" rel=\"nofollow noopener\" shape=\"rect\">www.vectorytx.com<\/a>.\n<\/p>\n<p>\n<b>About Annogen<br \/>\n<br \/><\/b>At Annogen we use our SuRE<sup>\u2122<\/sup> technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene &amp; cell therapy, as well as for recombinant protein production. In addition, we offer the AIM<sup>\u2122<\/sup> service to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches enables Research and Development to qualitatively interpret the non-coding genome in humans, animals and plants. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.annogen.bio%2F&amp;esheet=53281464&amp;newsitemid=20230119005364&amp;lan=en-US&amp;anchor=www.annogen.bio&amp;index=2&amp;md5=83be13b9d690aeaf4ac4c018a1af4500\" rel=\"nofollow noopener\" shape=\"rect\">www.annogen.bio<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>VectorY Therapeutics B.V.<\/b><br \/>Sariette Witte, Head of Communications<br \/>\n<br \/>E-mail: <a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x73;&#x61;&#x72;ie&#116;&#116;&#101;&#x2e;&#x77;&#x69;&#x74;&#x74;e&#64;&#118;&#101;&#99;&#x74;&#x6f;&#x72;&#x79;&#x74;x&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">s&#97;&#114;&#x69;&#x65;&#x74;&#x74;e&#46;&#119;&#105;&#x74;&#x74;&#x65;&#64;v&#101;&#99;&#x74;&#x6f;&#x72;yt&#120;&#46;&#x63;&#x6f;&#x6d;<\/a><br \/>Tel: +31 681 174 072\n<\/p>\n<p>\n<b>Instinctif Partners (media enquiries)<\/b><br \/>Melanie Toyne-Sewell \/ Giulia Lasagni \/ Manisha Kuttetira<br \/>\n<br \/>E-mail: <a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#86;&#101;&#99;&#116;&#x6f;&#x72;&#x59;&#x40;&#x69;&#x6e;&#x73;&#x74;&#x69;ncti&#102;&#46;&#99;&#111;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x56;&#101;&#x63;&#116;o&#x72;&#89;&#64;&#x69;&#110;&#x73;&#x74;i&#x6e;&#99;t&#x69;&#102;&#x2e;&#x63;o&#x6d;<\/a><br \/>Tel: +44 20 7457 2020\n<\/p>\n<p>\n<b>Annogen<\/b><br \/>P. Victor Schut, CBO<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x76;&#x69;&#99;&#x74;&#x6f;&#114;&#x40;&#x61;&#110;&#x6e;&#x6f;&#103;&#x65;&#x6e;&#46;&#x62;&#x69;&#111;\" rel=\"nofollow noopener\" shape=\"rect\">&#118;&#x69;c&#116;&#x6f;r&#64;&#x61;n&#110;&#x6f;g&#101;&#x6e;&#46;&#x62;&#x69;&#111;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Annogen to develop multiple CNS-cell specific promoters for VectorY programs AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind the SuRE\u2122 technology, today announced a research collaboration for the identification of CNS-cell specific synthetic promoters for use in VectorY\u2019s vectorized antibody programs. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53078","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Annogen to develop multiple CNS-cell specific promoters for VectorY programs AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind the SuRE\u2122 technology, today announced a research collaboration for the identification of CNS-cell specific synthetic promoters for use in VectorY\u2019s vectorized antibody programs. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-19T10:02:49+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters\",\"datePublished\":\"2023-01-19T10:02:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/\"},\"wordCount\":528,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/\",\"name\":\"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-01-19T10:02:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/","og_locale":"en_US","og_type":"article","og_title":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters - Pharma Trend","og_description":"Annogen to develop multiple CNS-cell specific promoters for VectorY programs AMSTERDAM&#8211;(BUSINESS WIRE)&#8211;VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases and Annogen, the company behind the SuRE\u2122 technology, today announced a research collaboration for the identification of CNS-cell specific synthetic promoters for use in VectorY\u2019s vectorized antibody programs. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-19T10:02:49+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters","datePublished":"2023-01-19T10:02:49+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/"},"wordCount":528,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/","url":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/","name":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-01-19T10:02:49+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53078"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53078\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}